Dynavax Technologies Co. (NASDAQ:DVAX) Shares Purchased by Peregrine Capital Management LLC

Peregrine Capital Management LLC increased its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 1.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 654,620 shares of the biopharmaceutical company’s stock after acquiring an additional 11,687 shares during the quarter. Peregrine Capital Management LLC owned about 0.50% of Dynavax Technologies worth $8,359,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in DVAX. Mizuho Markets Americas LLC increased its holdings in shares of Dynavax Technologies by 17.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock valued at $15,369,000 after acquiring an additional 204,475 shares during the period. Bank of Montreal Can increased its stake in Dynavax Technologies by 8.3% in the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock valued at $11,848,000 after purchasing an additional 82,449 shares during the period. Nordea Investment Management AB raised its holdings in shares of Dynavax Technologies by 42.7% in the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after buying an additional 232,690 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Dynavax Technologies during the third quarter worth about $8,291,000. Finally, Principal Financial Group Inc. grew its holdings in shares of Dynavax Technologies by 3.3% during the fourth quarter. Principal Financial Group Inc. now owns 596,590 shares of the biopharmaceutical company’s stock worth $7,618,000 after buying an additional 18,863 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

DVAX has been the subject of several analyst reports. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. HC Wainwright increased their price target on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th.

Dynavax Technologies Price Performance

Shares of DVAX opened at $12.93 on Wednesday. The firm has a market capitalization of $1.70 billion, a PE ratio of 99.47 and a beta of 1.32. The stock’s 50 day moving average is $12.80 and its two-hundred day moving average is $11.96. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $13.89. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.